论文部分内容阅读
目的观察胸腔注入尿激酶治疗包裹性结核性胸膜炎的临床价值。方法对确诊的包裹性结核性胸膜炎患者100例采用胸腔置管并经置管胸腔注入尿激酶治疗并与对照组比较,观察胸膜粘连程度,内科治疗率,住院天数,副反应发生率。结果胸腔置管并经置管胸腔注入尿激酶治疗包裹性结核性胸膜炎成功率达83%,降低手术治疗率25%,副反应发生率低,患者住院天数缩短。结论胸腔置管并经置管胸腔注入尿激酶治疗包裹性结核性胸膜炎安全,操作简便,成功率高,是治疗包裹性结核性胸膜炎有效的辅助方法,值得临床推广。
Objective To observe the clinical value of pleural injection of urokinase in the treatment of tuberculous pleurisy. Methods One hundred patients with tuberculous pleurisy diagnosed as tuberculous pleurisy were treated with thoracic catheterization and catheterized thoracic urokinase and compared with the control group. The degree of pleural adhesions, the rate of medical treatment, the days of hospitalization and the incidence of side effects were observed. Results The success rate of pleural tube insertion and catheterization of urokinase to treat tuberculous pleurisy was 83%, and the rate of surgical treatment was reduced by 25%. The incidence of side effects was low and the length of hospital stay was shortened. Conclusions Thoracic tube insertion and catheterization of urokinase through the tube into the thoracic cavity is safe and easy to operate and has a high success rate. It is an effective adjunct method for the treatment of tuberculous pleurisy and is worthy of clinical promotion.